H. Baird Radford
|
Chief Financial Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
194,144 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
H. Baird Radford
|
Chief Financial Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
27,600 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
H. Baird Radford
|
Chief Financial Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
163,426 |
0
(0%)
|
0%
|
|
-
|
Common Stock |
Robert E. Andreatta
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
99,590 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert E. Andreatta
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
7,700 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert E. Andreatta
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
37,600 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert E. Andreatta
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
7,700 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert E. Andreatta
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
16,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert E. Andreatta
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
41,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert E. Andreatta
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
86,762 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
16,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
55,380 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
18,800 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
7,700 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
7,700 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
99,590 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
86,762 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Steven P. James
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
41,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
462,325 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
738,104 |
0
(0%)
|
1%
|
|
-
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
320,300 |
0
(0%)
|
0%
|
|
-
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
912,500 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
290,022 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
306,960 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
250,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
2,000,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Dolca Thomas
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
41,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Dolca Thomas
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
154,786 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Amy L. Ladd
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
41,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Amy L. Ladd
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
233,177 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Amy L. Ladd
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
86,762 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Neil Graham
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
41,000 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Neil Graham
|
Director |
Sale or transfer of securities back to the company at price $ 0.00 per share. |
15 May 2025 |
154,786 |
0
|
-
|
|
-
|
Stock Option (right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.26 per share. |
06 Mar 2025 |
31,370 |
738,104
(1%)
|
0%
|
0.3 |
8,156
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.26 per share. |
05 Mar 2025 |
14,161 |
163,426
(0%)
|
0%
|
0.3 |
3,682
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.26 per share. |
05 Mar 2025 |
20,017 |
512,630
(1%)
|
0%
|
0.3 |
5,204
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. |
06 Dec 2024 |
13,138 |
177,587
(0%)
|
0%
|
1.1 |
14,452
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. |
06 Dec 2024 |
21,116 |
532,647
(1%)
|
0%
|
1.1 |
23,228
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.10 per share. |
05 Dec 2024 |
32,466 |
769,474
(1%)
|
0%
|
1.1 |
35,713
|
Common Stock |
Chin Lee
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.13 per share. |
04 Dec 2024 |
10,634 |
275,046
(0%)
|
0%
|
1.1 |
12,016
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.58 per share. |
11 Sep 2024 |
37,311 |
801,940
(1%)
|
0%
|
0.6 |
21,640
|
Common Stock |
Chin Lee
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.65 per share. |
09 Sep 2024 |
45,320 |
285,680
(0%)
|
0%
|
0.7 |
29,458
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.65 per share. |
06 Sep 2024 |
13,665 |
190,725
(0%)
|
0%
|
0.6 |
8,882
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.65 per share. |
06 Sep 2024 |
21,961 |
553,763
(1%)
|
0%
|
0.7 |
14,275
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Sale of securities on an exchange or to another person at price $ 1.01 per share. |
28 Jun 2024 |
87,064 |
204,390
(0%)
|
0%
|
1.0 |
87,935
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.12 per share. |
07 Jun 2024 |
24,749 |
572,724
(1%)
|
0%
|
1.1 |
27,719
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.14 per share. |
06 Jun 2024 |
37,525 |
836,251
(1%)
|
0%
|
1.1 |
42,779
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.19 per share. |
04 Jun 2024 |
14,565 |
291,454
(0%)
|
0%
|
1.2 |
17,332
|
Common Stock |
Robert E. Andreatta
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 May 2024 |
41,000 |
41,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Steven P. James
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 May 2024 |
41,000 |
41,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Dolca Thomas
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 May 2024 |
41,000 |
41,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Amy L. Ladd
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 May 2024 |
41,000 |
41,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Neil Graham
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 May 2024 |
41,000 |
41,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Paul Walker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
24 May 2024 |
41,000 |
41,000
|
-
|
|
-
|
Stock Option (Right to buy) |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.35 per share. |
06 Mar 2024 |
32,142 |
306,019
(0%)
|
0%
|
1.4 |
43,392
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.44 per share. |
05 Mar 2024 |
47,392 |
597,473
(1%)
|
0%
|
1.4 |
68,244
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.48 per share. |
04 Mar 2024 |
70,910 |
873,776
(1%)
|
0%
|
1.5 |
104,947
|
Common Stock |
Alexander Robert
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Feb 2024 |
2,000,000 |
2,000,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Tomasi Adam
|
President |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Feb 2024 |
1,200,000 |
1,200,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Lee Chin
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Feb 2024 |
500,000 |
500,000
|
-
|
|
-
|
Stock Option (Right to buy) |
H. Radford Baird
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
16 Feb 2024 |
900,000 |
900,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Alexander Robert
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.50 per share. |
04 Dec 2023 |
24,753 |
941,686
(1%)
|
0%
|
2.5 |
61,883
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.50 per share. |
04 Dec 2023 |
16,054 |
641,865
(1%)
|
0%
|
2.5 |
40,135
|
Common Stock |
Craig Paterson
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.50 per share. |
04 Dec 2023 |
6,992 |
323,472
(0%)
|
0%
|
2.5 |
17,480
|
Common Stock |
Baird H. Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.50 per share. |
04 Dec 2023 |
8,380 |
338,161
(0%)
|
0%
|
2.5 |
20,950
|
Common Stock |
Neil Graham
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
28 Aug 2023 |
154,786 |
154,786
|
-
|
|
-
|
Stock Option (Right to buy) |
Dolca Thomas
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Aug 2023 |
154,786 |
154,786
|
-
|
|
-
|
Stock Option (Right to buy) |
Everett Rand Sutherland
|
Director |
|
01 Aug 2023 |
154,786 |
154,786
|
-
|
|
-
|
Stock Option (Right to buy) |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.13 per share. |
02 Jun 2023 |
8,942 |
356,052
(0%)
|
0%
|
5.1 |
45,872
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.13 per share. |
02 Jun 2023 |
26,415 |
957,862
(1%)
|
0%
|
5.1 |
135,509
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.13 per share. |
02 Jun 2023 |
17,129 |
673,138
(1%)
|
0%
|
5.1 |
87,872
|
Common Stock |
Craig Paterson
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.13 per share. |
02 Jun 2023 |
7,460 |
338,399
(0%)
|
0%
|
5.1 |
38,270
|
Common Stock |
Daniel S. Janney
|
Director |
|
25 May 2023 |
86,762 |
86,762
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert E. Andreatta
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2023 |
86,762 |
86,762
|
-
|
|
-
|
Stock Option (Right to buy) |
Steven P. James
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2023 |
86,762 |
86,762
|
-
|
|
-
|
Stock Option (Right to buy) |
Paul Walker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2023 |
86,762 |
86,762
|
-
|
|
-
|
Stock Option (Right to buy) |
Amy L. Ladd
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2023 |
86,762 |
86,762
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.24 per share. |
07 Mar 2023 |
66,274 |
984,277
(2%)
|
0%
|
6.2 |
413,550
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.40 per share. |
07 Mar 2023 |
9,143 |
1,050,551
(2%)
|
0%
|
6.4 |
58,515
|
Common Stock |
Adam Tomasi
|
President |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.34 per share. |
06 Mar 2023 |
57,467 |
690,267
(1%)
|
0%
|
5.3 |
306,874
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.75 per share. |
03 Mar 2023 |
33,907 |
364,994
(0%)
|
0%
|
5.7 |
194,965
|
Common Stock |
Craig Paterson
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.83 per share. |
02 Mar 2023 |
26,615 |
345,859
(0%)
|
0%
|
5.8 |
155,165
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
126,640 |
398,901
(0%)
|
0%
|
|
0
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
194,144 |
194,144
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
462,325 |
462,325
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
301,575 |
1,056,694
(2%)
|
0%
|
|
0
|
Common Stock |
Adam Tomasi
|
President |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
195,997 |
744,734
(1%)
|
0%
|
|
0
|
Common Stock |
Adam Tomasi
|
President |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
300,471 |
300,471
|
-
|
|
-
|
Stock Option (Right to buy) |
Craig Paterson
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
157,428 |
157,428
|
-
|
|
-
|
Stock Option (Right to buy) |
Craig Paterson
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jan 2023 |
102,690 |
372,474
(0%)
|
0%
|
|
0
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.11 per share. |
02 Dec 2022 |
3,843 |
272,261
(0%)
|
0%
|
8.1 |
31,167
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.11 per share. |
02 Dec 2022 |
15,152 |
755,119
(1%)
|
0%
|
8.1 |
122,883
|
Common Stock |
Adam Tomasi
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.11 per share. |
02 Dec 2022 |
9,783 |
548,737
(1%)
|
0%
|
8.1 |
79,340
|
Common Stock |
Craig Paterson
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.11 per share. |
02 Dec 2022 |
4,863 |
269,784
(0%)
|
0%
|
8.1 |
39,439
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
21 Sep 2022 |
475,000 |
2,546,147
(5%)
|
0%
|
5.0 |
2,384,500
|
Common Stock |
Paul Walker
|
Director |
Purchase of securities on an exchange or from another person at price $ 5.02 per share. |
21 Sep 2022 |
3,386,400 |
3,386,400
(6%)
|
6%
|
5.0 |
16,999,728
|
Common Stock |
Paul Walker
|
Director |
Purchase of securities on an exchange or from another person at price $ 5.02 per share. |
21 Sep 2022 |
597,600 |
2,760,860
(5%)
|
1%
|
5.0 |
2,999,952
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.54 per share. |
02 Sep 2022 |
585 |
276,104
(0%)
|
0%
|
4.5 |
2,656
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.54 per share. |
02 Sep 2022 |
8,316 |
770,271
(1%)
|
0%
|
4.5 |
37,755
|
Common Stock |
Adam Tomasi
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.54 per share. |
02 Sep 2022 |
5,369 |
558,520
(1%)
|
0%
|
4.5 |
24,375
|
Common Stock |
Craig Paterson
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.54 per share. |
02 Sep 2022 |
1,129 |
274,647
(0%)
|
0%
|
4.5 |
5,126
|
Common Stock |
Margaret Nell Fitzgerald
|
General Counsel and Secretary |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 4.54 per share. |
02 Sep 2022 |
335 |
153,128
(0%)
|
0%
|
4.5 |
1,521
|
Common Stock |
Amy L. Ladd
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
21 Jul 2022 |
233,177 |
233,177
|
-
|
|
-
|
Stock Option (Right to buy) |
H. Baird Radford
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. |
02 Jun 2022 |
2,274 |
276,689
(0%)
|
0%
|
2.8 |
6,254
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. |
02 Jun 2022 |
8,084 |
778,587
(1%)
|
0%
|
2.8 |
22,231
|
Common Stock |
Adam Tomasi
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. |
02 Jun 2022 |
5,219 |
563,889
(1%)
|
0%
|
2.7 |
14,352
|
Common Stock |
Craig Paterson
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. |
02 Jun 2022 |
226 |
275,776
(0%)
|
0%
|
2.8 |
622
|
Common Stock |
Margaret Nell Fitzgerald
|
General Counsel and Secretary |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.75 per share. |
02 Jun 2022 |
318 |
150,463
(0%)
|
0%
|
2.8 |
875
|
Common Stock |
Daniel S. Janney
|
Director |
|
25 May 2022 |
99,590 |
99,590
|
-
|
|
-
|
Stock Option (Right to buy) |
John P. Mckearn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2022 |
99,590 |
99,590
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert E. Andreatta
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2022 |
99,590 |
99,590
|
-
|
|
-
|
Stock Option (Right to buy) |
Steven P. James
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2022 |
99,590 |
99,590
|
-
|
|
-
|
Stock Option (Right to buy) |
Paul Walker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2022 |
99,590 |
99,590
|
-
|
|
-
|
Stock Option (Right to Buy) |
Margaret Nell Fitzgerald
|
General Counsel and Secretary |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
19 Apr 2022 |
57,637 |
150,781
(0%)
|
0%
|
|
0
|
Common Stock |
Mark Asbury
|
CLO, GC and Secretary |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.38 per share. |
02 Mar 2022 |
1,680 |
226,935
(0%)
|
0%
|
5.4 |
9,038
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.38 per share. |
02 Mar 2022 |
8,215 |
786,671
(1%)
|
0%
|
5.4 |
44,197
|
Common Stock |
Adam Tomasi
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 5.38 per share. |
02 Mar 2022 |
5,582 |
569,108
(1%)
|
0%
|
5.4 |
30,031
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 Feb 2022 |
237,608 |
278,963
(0%)
|
0%
|
|
0
|
Common Stock |
Mark Asbury
|
CLO, GC and Secretary |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 Feb 2022 |
140,490 |
228,615
(0%)
|
0%
|
|
0
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 Feb 2022 |
529,323 |
794,886
(1%)
|
1%
|
|
0
|
Common Stock |
Adam Tomasi
|
President and COO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 Feb 2022 |
344,060 |
574,690
(1%)
|
0%
|
|
0
|
Common Stock |
Steven P. James
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.52 per share. |
28 Sep 2021 |
4,000 |
4,000
(0%)
|
0%
|
0.5 |
2,100
|
Common Stock |
Steven P. James
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
28 Sep 2021 |
4,000 |
55,380
|
-
|
|
-
|
Stock Option (Right to buy) |
Steven P. James
|
Director |
Sale of securities on an exchange or to another person at price $ 108.12 per share. |
28 Sep 2021 |
4,000 |
0
(0%)
|
0%
|
108.1 |
432,480
|
Common Stock |
Mark Asbury
|
CLO, GC and Secretary |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.66 per share. |
02 Sep 2021 |
698 |
61,810
(0%)
|
0%
|
91.7 |
63,979
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.66 per share. |
02 Sep 2021 |
3,985 |
233,810
(0%)
|
0%
|
91.7 |
365,265
|
Common Stock |
Adam Tomasi
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 91.66 per share. |
02 Sep 2021 |
2,346 |
210,022
(0%)
|
0%
|
91.7 |
215,034
|
Common Stock |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. |
31 Aug 2021 |
64,148 |
212,368
(0%)
|
0%
|
4.3 |
276,638
|
Common Stock |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
31 Aug 2021 |
64,148 |
88,036
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
14 Jun 2021 |
20,000 |
168,220
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President and COO |
Sale of securities on an exchange or to another person at price $ 91.62 per share. |
14 Jun 2021 |
20,000 |
148,220
(0%)
|
0%
|
91.6 |
1,832,362
|
Common Stock |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
14 Jun 2021 |
20,000 |
168,220
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President and COO |
Sale of securities on an exchange or to another person at price $ 91.03 per share. |
14 Jun 2021 |
20,000 |
148,220
(0%)
|
0%
|
91.0 |
1,820,502
|
Common Stock |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
14 Jun 2021 |
20,000 |
506,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
14 Jun 2021 |
20,000 |
486,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President and COO |
Sale of securities on an exchange or to another person at price $ 90.26 per share. |
03 Jun 2021 |
642 |
150,707
(0%)
|
0%
|
90.3 |
57,947
|
Common Stock |
Adam Tomasi
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 92.20 per share. |
03 Jun 2021 |
1,777 |
151,349
(0%)
|
0%
|
92.2 |
163,839
|
Common Stock |
Adam Tomasi
|
President and COO |
Sale of securities on an exchange or to another person at price $ 92.03 per share. |
03 Jun 2021 |
2,487 |
148,220
(0%)
|
0%
|
92.0 |
228,879
|
Common Stock |
Daniel S. Janney
|
Director |
|
25 May 2021 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to buy) |
John P. Mckearn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2021 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert E. Andreatta
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2021 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to buy) |
Steven P. James
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2021 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to buy) |
Paul Walker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2021 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to buy) |
Natalie C. Holles
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
25 May 2021 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 102.32 per share. |
17 May 2021 |
14,517 |
245,395
(0%)
|
0%
|
102.3 |
1,485,379
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 May 2021 |
14,517 |
985,083
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 May 2021 |
14,517 |
970,566
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
17 May 2021 |
14,516 |
956,050
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 99.69 per share. |
17 May 2021 |
5,484 |
347,716
(0%)
|
0%
|
99.7 |
546,700
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 102.29 per share. |
17 May 2021 |
5,484 |
342,232
(0%)
|
0%
|
102.3 |
560,958
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 98.89 per share. |
17 May 2021 |
5,482 |
336,750
(0%)
|
0%
|
98.9 |
542,115
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
17 May 2021 |
14,517 |
259,912
(0%)
|
0%
|
0.7 |
9,980
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 99.68 per share. |
17 May 2021 |
14,517 |
245,395
(0%)
|
0%
|
99.7 |
1,447,055
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
17 May 2021 |
14,517 |
259,912
(0%)
|
0%
|
0.7 |
9,980
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
17 May 2021 |
14,516 |
259,911
(0%)
|
0%
|
0.7 |
9,980
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 98.94 per share. |
17 May 2021 |
14,516 |
245,395
(0%)
|
0%
|
98.9 |
1,436,213
|
Common Stock |
Adam Tomasi
|
President and COO |
Sale of securities on an exchange or to another person at price $ 99.23 per share. |
10 May 2021 |
20,000 |
153,126
(0%)
|
0%
|
99.2 |
1,984,600
|
Common Stock |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 May 2021 |
20,000 |
566,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 May 2021 |
20,000 |
546,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
10 May 2021 |
20,000 |
526,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
10 May 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President and COO |
Sale of securities on an exchange or to another person at price $ 96.02 per share. |
10 May 2021 |
20,000 |
153,126
(0%)
|
0%
|
96.0 |
1,920,400
|
Common Stock |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
10 May 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President and COO |
Sale of securities on an exchange or to another person at price $ 97.79 per share. |
10 May 2021 |
20,000 |
153,126
(0%)
|
0%
|
97.8 |
1,955,800
|
Common Stock |
Adam Tomasi
|
President and COO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
10 May 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
H. Baird Radford
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
19 Apr 2021 |
27,600 |
27,600
|
-
|
|
-
|
Stock Option (Right to buy) |
H. Baird Radford
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
19 Apr 2021 |
17,100 |
17,100
(0%)
|
0%
|
|
0
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Sale of securities on an exchange or to another person at price $ 107.77 per share. |
12 Apr 2021 |
20,000 |
153,126
(0%)
|
0%
|
107.8 |
2,155,400
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Apr 2021 |
20,000 |
626,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Apr 2021 |
20,000 |
606,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
12 Apr 2021 |
20,000 |
586,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
12 Apr 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Sale of securities on an exchange or to another person at price $ 104.40 per share. |
12 Apr 2021 |
20,000 |
153,126
(0%)
|
0%
|
104.4 |
2,088,000
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
12 Apr 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Sale of securities on an exchange or to another person at price $ 103.08 per share. |
12 Apr 2021 |
20,000 |
153,126
(0%)
|
0%
|
103.1 |
2,061,600
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
12 Apr 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Apr 2021 |
10,000 |
282,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Henrik S. Rasmussen
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 111.68 per share. |
01 Apr 2021 |
10,000 |
101,819
(0%)
|
0%
|
111.7 |
1,116,800
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. |
01 Apr 2021 |
10,000 |
111,819
(0%)
|
0%
|
1.2 |
11,625
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 113.06 per share. |
01 Apr 2021 |
20,000 |
101,819
(0%)
|
0%
|
113.1 |
2,261,200
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. |
01 Apr 2021 |
20,000 |
121,819
(0%)
|
0%
|
1.2 |
23,250
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 114.40 per share. |
01 Apr 2021 |
20,000 |
101,819
(0%)
|
0%
|
114.4 |
2,288,000
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. |
01 Apr 2021 |
20,000 |
121,819
(0%)
|
0%
|
1.2 |
23,250
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Apr 2021 |
20,000 |
292,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Apr 2021 |
20,000 |
312,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
26 Mar 2021 |
2,500 |
56,293
(0%)
|
0%
|
116.1 |
290,225
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
26 Mar 2021 |
14,808 |
58,793
(0%)
|
0%
|
115.0 |
1,703,068
|
Common Stock |
John P. Mckearn
|
Director |
Gift of securities by or to the insider at price $ 0.00 per share. |
26 Mar 2021 |
1,200 |
0
(0%)
|
0%
|
|
0
|
Common Stock |
John P. Mckearn
|
Director |
Sale of securities on an exchange or to another person at price $ 115.00 per share. |
26 Mar 2021 |
7,439 |
1,200
(0%)
|
0%
|
115 |
855,485
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
22 Mar 2021 |
9,030 |
77,719
(0%)
|
0%
|
119.5 |
1,078,724
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
22 Mar 2021 |
4,118 |
73,601
(0%)
|
0%
|
120.2 |
495,066
|
Common Stock |
Steven P. James
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.53 per share. |
16 Mar 2021 |
3,500 |
3,500
(0%)
|
0%
|
0.5 |
1,838
|
Common Stock |
Steven P. James
|
Director |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
16 Mar 2021 |
3,500 |
59,380
|
-
|
|
-
|
Stock Option (Right to buy) |
Steven P. James
|
Director |
Sale of securities on an exchange or to another person at price $ 121.65 per share. |
16 Mar 2021 |
3,500 |
0
(0%)
|
0%
|
121.7 |
425,775
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
15 Mar 2021 |
20,000 |
265,395
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Mar 2021 |
20,000 |
1,039,600
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Mar 2021 |
20,000 |
1,019,600
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
15 Mar 2021 |
20,000 |
999,600
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
15 Mar 2021 |
20,000 |
265,395
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 122.78 per share. |
15 Mar 2021 |
20,000 |
245,395
(0%)
|
0%
|
122.8 |
2,455,600
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
15 Mar 2021 |
20,000 |
265,395
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 121.76 per share. |
15 Mar 2021 |
20,000 |
245,395
(0%)
|
0%
|
121.8 |
2,435,200
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Sale of securities on an exchange or to another person at price $ 121.14 per share. |
15 Mar 2021 |
20,000 |
245,395
(0%)
|
0%
|
121.1 |
2,422,800
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
12 Mar 2021 |
4,071 |
93,457
(0%)
|
0%
|
124.2 |
505,537
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
12 Mar 2021 |
6,708 |
86,749
(0%)
|
0%
|
124.6 |
835,548
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
09 Mar 2021 |
100 |
103,534
(0%)
|
0%
|
125 |
12,500
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
09 Mar 2021 |
6,006 |
97,528
(0%)
|
0%
|
124.6 |
748,468
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
08 Mar 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Mar 2021 |
20,000 |
686,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Mar 2021 |
20,000 |
666,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
08 Mar 2021 |
20,000 |
646,400
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
08 Mar 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Sale of securities on an exchange or to another person at price $ 122.78 per share. |
08 Mar 2021 |
20,000 |
153,126
(0%)
|
0%
|
122.8 |
2,455,600
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.69 per share. |
08 Mar 2021 |
20,000 |
173,126
(0%)
|
0%
|
0.7 |
13,750
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Sale of securities on an exchange or to another person at price $ 121.78 per share. |
08 Mar 2021 |
20,000 |
153,126
(0%)
|
0%
|
121.8 |
2,435,600
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Sale of securities on an exchange or to another person at price $ 121.78 per share. |
08 Mar 2021 |
20,000 |
153,126
(0%)
|
0%
|
121.8 |
2,435,600
|
Common Stock |
Mark Asbury
|
CLO, GC and Secretary |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.82 per share. |
02 Mar 2021 |
733 |
63,242
(0%)
|
0%
|
117.8 |
86,362
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.82 per share. |
02 Mar 2021 |
3,890 |
245,395
(0%)
|
0%
|
117.8 |
458,320
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.82 per share. |
02 Mar 2021 |
1,717 |
156,315
(0%)
|
0%
|
117.8 |
202,297
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Sale of securities on an exchange or to another person at price $ 113.56 per share. |
02 Mar 2021 |
3,189 |
153,126
(0%)
|
0%
|
113.6 |
362,143
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. |
01 Mar 2021 |
20,000 |
125,087
(0%)
|
0%
|
1.2 |
23,250
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 117.32 per share. |
01 Mar 2021 |
20,000 |
105,087
(0%)
|
0%
|
117.3 |
2,346,400
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 117.82 per share. |
01 Mar 2021 |
1,316 |
103,771
(0%)
|
0%
|
117.8 |
155,051
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. |
01 Mar 2021 |
20,000 |
123,771
(0%)
|
0%
|
1.2 |
23,250
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 113.00 per share. |
01 Mar 2021 |
20,000 |
103,771
(0%)
|
0%
|
113 |
2,260,000
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 112.83 per share. |
01 Mar 2021 |
1,952 |
101,819
(0%)
|
0%
|
112.8 |
220,244
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Mar 2021 |
20,000 |
372,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Mar 2021 |
20,000 |
352,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
01 Mar 2021 |
20,000 |
332,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Henrik S. Rasmussen
|
Chief Medical Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.16 per share. |
01 Mar 2021 |
20,000 |
125,087
(0%)
|
0%
|
1.2 |
23,250
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Sale of securities on an exchange or to another person at price $ 120.66 per share. |
01 Mar 2021 |
20,000 |
105,087
(0%)
|
0%
|
120.7 |
2,413,200
|
Common Stock |
John P. Mckearn
|
Director |
Other type of transaction at price $ 0.00 per share. |
18 Feb 2021 |
8,016 |
8,639
(0%)
|
0%
|
|
0
|
Common Stock |
John P. Mckearn
|
Director |
Other type of transaction at price $ 0.00 per share. |
18 Feb 2021 |
47,494 |
4,887,932
(10%)
|
0%
|
|
0
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Other type of transaction at price $ 0.00 per share. |
04 Jan 2021 |
862,574 |
4,935,426
(10%)
|
1%
|
|
0
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Other type of transaction at price $ 0.00 per share. |
04 Jan 2021 |
623 |
623
(0%)
|
0%
|
|
0
|
Common Stock |
Natalie C. Holles
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
04 Jan 2021 |
4,000 |
4,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
29 Dec 2020 |
8,240 |
306,960
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, Chief Executive Officer |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. |
29 Dec 2020 |
8,240 |
241,105
(0%)
|
0%
|
4.3 |
35,535
|
Common Stock |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. |
29 Dec 2020 |
5,416 |
152,184
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
President, COO and CFO |
Exercise or conversion of derivative security received from the company (such as an option) at price $ 4.31 per share. |
29 Dec 2020 |
5,416 |
157,757
(0%)
|
0%
|
4.3 |
23,357
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.04 per share. |
01 Dec 2020 |
3,954 |
104,812
(0%)
|
0%
|
99.0 |
391,604
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Dec 2020 |
52,300 |
108,766
(0%)
|
0%
|
|
0
|
Common Stock |
Mark Asbury
|
CLO, GC and Secretary |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Dec 2020 |
32,400 |
66,234
(0%)
|
0%
|
|
0
|
Common Stock |
Mark Asbury
|
CLO, GC and Secretary |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.04 per share. |
01 Dec 2020 |
2,977 |
63,257
(0%)
|
0%
|
99.0 |
294,842
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.04 per share. |
01 Dec 2020 |
14,501 |
232,865
(0%)
|
0%
|
99.0 |
1,436,179
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Dec 2020 |
121,600 |
247,366
(0%)
|
0%
|
|
0
|
Common Stock |
Adam Tomasi
|
President and COO |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.04 per share. |
01 Dec 2020 |
8,825 |
152,341
(0%)
|
0%
|
99.0 |
874,028
|
Common Stock |
Adam Tomasi
|
President and COO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Dec 2020 |
78,500 |
161,166
(0%)
|
0%
|
|
0
|
Common Stock |
Leo Redmond
|
Chief Financial Officer |
Payment of exercise price or tax liability using portion of securities received from the company at price $ 99.04 per share. |
01 Dec 2020 |
2,472 |
51,958
(0%)
|
0%
|
99.0 |
244,827
|
Common Stock |
Leo Redmond
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
01 Dec 2020 |
26,900 |
54,430
(0%)
|
0%
|
|
0
|
Common Stock |
Daniel S. Janney
|
Director |
|
26 May 2020 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to Buy) |
John P. Mckearn
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 May 2020 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to Buy) |
Robert E. Andreatta
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 May 2020 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to Buy) |
Steven P. James
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 May 2020 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to Buy) |
Paul Walker
|
Director |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 May 2020 |
7,700 |
7,700
|
-
|
|
-
|
Stock Option (Right to Buy) |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 71.04 per share. |
12 May 2020 |
1,150,000 |
5,750,506
(11%)
|
2%
|
71.0 |
81,696,000
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
29 Nov 2019 |
52,300 |
55,077
(0%)
|
0%
|
|
0
|
Common Stock |
Mark Asbury
|
Other |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
29 Nov 2019 |
32,400 |
33,117
(0%)
|
0%
|
|
0
|
Common Stock |
Robert Alexander
|
Director, Chief Executive Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
29 Nov 2019 |
121,600 |
124,377
(0%)
|
0%
|
|
0
|
Common Stock |
Adam Tomasi
|
President and COO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
29 Nov 2019 |
78,500 |
81,277
(0%)
|
0%
|
|
0
|
Common Stock |
Leo Redmond
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
29 Nov 2019 |
26,900 |
26,900
(0%)
|
0%
|
|
0
|
Common Stock |
Leo Redmond
|
Chief Financial Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
02 Aug 2019 |
120,000 |
120,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 40.58 per share. |
07 Jun 2019 |
7,100 |
6,900,738
(14%)
|
0%
|
40.6 |
288,118
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 41.05 per share. |
07 Jun 2019 |
232 |
6,900,506
(14%)
|
0%
|
41.1 |
9,524
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 39.62 per share. |
07 Jun 2019 |
31,400 |
6,907,838
(14%)
|
0%
|
39.6 |
1,244,068
|
Common Stock |
Daniel S. Janney
|
None |
|
06 Jun 2019 |
16,000 |
16,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
John P. Mckearn
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jun 2019 |
16,000 |
16,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Robert E. Andreatta
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jun 2019 |
16,000 |
16,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Steven P. James
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jun 2019 |
16,000 |
16,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
Paul Walker
|
None |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
06 Jun 2019 |
16,000 |
16,000
|
-
|
|
-
|
Stock Option (Right to Buy) |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 39.49 per share. |
04 Jun 2019 |
6,248 |
7,004,631
(14%)
|
0%
|
39.5 |
246,734
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 40.40 per share. |
04 Jun 2019 |
900 |
7,032,073
(14%)
|
0%
|
40.4 |
36,360
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 39.50 per share. |
04 Jun 2019 |
21,194 |
7,010,879
(14%)
|
0%
|
39.5 |
837,163
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 39.81 per share. |
04 Jun 2019 |
17,500 |
6,987,131
(14%)
|
0%
|
39.8 |
696,675
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 40.01 per share. |
04 Jun 2019 |
47,893 |
6,939,238
(14%)
|
0%
|
40.0 |
1,916,199
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 43.27 per share. |
30 May 2019 |
600 |
7,086,279
(14%)
|
0%
|
43.3 |
25,962
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 39.63 per share. |
30 May 2019 |
22,049 |
7,035,573
(14%)
|
0%
|
39.6 |
873,802
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 40.16 per share. |
30 May 2019 |
4,257 |
7,057,622
(14%)
|
0%
|
40.2 |
170,961
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 38.97 per share. |
30 May 2019 |
2,600 |
7,032,973
(14%)
|
0%
|
39.0 |
101,322
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 39.12 per share. |
30 May 2019 |
17,321 |
7,061,879
(14%)
|
0%
|
39.1 |
677,598
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 40.06 per share. |
30 May 2019 |
7,079 |
7,079,200
(14%)
|
0%
|
40.1 |
283,585
|
Common Stock |
Mark Asbury
|
Other |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
26 Apr 2019 |
39,910 |
39,910
|
-
|
|
-
|
Stock Option (Right to Buy) |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 36.33 per share. |
16 Apr 2019 |
35,889 |
7,110,307
(14%)
|
0%
|
36.3 |
1,303,847
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 34.82 per share. |
16 Apr 2019 |
1,028 |
7,086,879
(14%)
|
0%
|
34.8 |
35,795
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 36.07 per share. |
16 Apr 2019 |
2,400 |
7,087,907
(14%)
|
0%
|
36.1 |
86,568
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 36.33 per share. |
16 Apr 2019 |
20,000 |
7,090,307
(14%)
|
0%
|
36.3 |
726,600
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 37.23 per share. |
16 Apr 2019 |
22,679 |
7,153,517
(14%)
|
0%
|
37.2 |
844,339
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 36.80 per share. |
16 Apr 2019 |
7,321 |
7,146,196
(14%)
|
0%
|
36.8 |
269,413
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 35.03 per share. |
15 Feb 2019 |
9,228 |
7,309,187
(15%)
|
0%
|
35.0 |
323,257
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 34.34 per share. |
15 Feb 2019 |
92,219 |
7,176,196
(14%)
|
0%
|
34.3 |
3,166,800
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 34.72 per share. |
15 Feb 2019 |
40,772 |
7,268,415
(14%)
|
0%
|
34.7 |
1,415,604
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 43.26 per share. |
24 Jan 2019 |
12,955 |
7,278,533
(14%)
|
0%
|
43.3 |
560,433
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Sale of securities on an exchange or to another person at price $ 42.42 per share. |
24 Jan 2019 |
39,882 |
7,318,415
(15%)
|
0%
|
42.4 |
1,691,794
|
Common Stock |
Henrik S. Rasmussen
|
Chief Medical Officer |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Oct 2018 |
80,000 |
80,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Robert Alexander
|
Director, President and CEO |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Oct 2018 |
250,000 |
250,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Adam Tomasi
|
COO, CFO and Secretary |
Grant, award, or other acquisition of securities at price $ 0.00 per share. |
09 Oct 2018 |
125,000 |
125,000
|
-
|
|
-
|
Stock Option (Right to buy) |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
23 Jul 2018 |
11,269,200 |
11,269,200
(27%)
|
27%
|
|
0
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
23 Jul 2018 |
250,000 |
11,519,200
(28%)
|
0%
|
18 |
4,500,000
|
Common Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
23 Jul 2018 |
1,239,007 |
0
|
-
|
|
-
|
Series B Preferred Stock |
Daniel S. Janney
|
Director, Ten Percent Owner |
|
23 Jul 2018 |
10,030,193 |
0
|
-
|
|
-
|
Series A Preferred Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
|
23 Jul 2018 |
777,417 |
0
|
-
|
|
-
|
Series B Preferred Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
Purchase of securities on an exchange or from another person at price $ 18.00 per share. |
23 Jul 2018 |
111,111 |
7,371,252
(18%)
|
0%
|
18 |
1,999,998
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
|
23 Jul 2018 |
7,260,141 |
7,260,141
(17%)
|
17%
|
|
0
|
Common Stock |
John P. Mckearn
|
Director, Ten Percent Owner |
|
23 Jul 2018 |
6,482,724 |
0
|
-
|
|
-
|
Series A Preferred Stock |